Filing Flows › Crispr Therapeutics AG (CRSP) › Q3 2025
Crispr Therapeutics AG (CRSP) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Crispr Therapeutics AG (CRSP) reported revenue of $889K for the third quarter 2025 (Q3 2025), +48% from a year earlier and -0.3% from the quarter before.
Crispr Therapeutics AG, Q3 2025: revenue $889K (+48% year over year), net loss $106M, operating cash flow −$84.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $889K | -0.3% | +48% |
| Operating profit | −$132M | — | — |
| Net earnings | −$106M | — | — |
| Operating cash flow | −$84.6M | — | — |
What changed
Revenue was $889K in Q3 2025, up 48% year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $132.1M, an operating margin of -14854.8%. Total costs grew 20% against revenue growth of 48%. The fastest-growing cost line was Other operating costs (+412%). The quarter ended with a net loss of $106.4M, narrower than the previous quarter's $208.5M loss. Non-operating items added $26.2M, -25% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$84.6M. Non-cash charges added back $4.4M of depreciation and amortization and $16.6M of share-based compensation. Capital expenditures of $74K exceeded it, leaving free cash flow of −$84.7M.
Questions
What was Crispr Therapeutics AG's revenue in the third quarter 2025?
Crispr Therapeutics AG (CRSP) reported revenue of $889K for the third quarter 2025 (Q3 2025), +48% from a year earlier and -0.3% from the quarter before.